| Molecular Oncology (DR) | |||||
| PhD | TR-NQF-HE: Level 8 | QF-EHEA: Third Cycle | EQF-LLL: Level 8 | ||
| Course Code: | MONK6205 | ||||
| Course Name: | Tumor Immunology | ||||
| Semester: | Fall | ||||
| Course Credits: |
|
||||
| Language of instruction: | Turkish | ||||
| Course Condition: | |||||
| Does the Course Require Work Experience?: | No | ||||
| Type of course: | Departmental Elective | ||||
| Course Level: |
|
||||
| Mode of Delivery: | E-Learning | ||||
| Course Coordinator: | Prof. Dr. PINAR YURDAKUL MESUTOĞLU | ||||
| Course Lecturer(s): | Prof Dr Pınar Yurdakul-Mesutoğlu | ||||
| Course Assistants: |
| Course Objectives: | The main purpose of this course is to enable students to adopt the basics of tumor immunology and immunotherapy approaches, to discuss developments in the light of the literature and to prepare presentations on determined topics. The contributions of immune system molecules, cells and different pathways to the development and prevention of cancers are discussed |
| Course Content: | Basic biological concepts in tumor immunology; cellular and humoral immune response against tumors; cells in the tumor microenvironment and their effects; tumor antigens, immune surveillance and immune editing of tumor; escape mechanisms of the tumor from the immune system; angiogenesis, adhesion molecules and apoptosis mechanisms; immunotherapies as well as targeted therapies in cancer. |
|
The students who have succeeded in this course;
|
| Week | Subject | Related Preparation |
| 1) | Basic Clinical Immunology | Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai - Basic Immunology_ Functions and Disorders of the Immune System (2019, Elsevier) |
| 2) | An Introduction to Tumor Immunology-1 | Abul K. Abbas MBBS, Andrew H. Lichtman MD PhD, Shiv Pillai MBBS - Cellular and Molecular Immunology (2021, Elsevier) |
| 3) | An Introduction to Tumor Immunology-2 | Abul K. Abbas MBBS, Andrew H. Lichtman MD PhD, Shiv Pillai MBBS - Cellular and Molecular Immunology (2021, Elsevier) |
| 4) | Tumor Antigens | Abul K. Abbas MBBS, Andrew H. Lichtman MD PhD, Shiv Pillai MBBS - Cellular and Molecular Immunology (2021, Elsevier) |
| 5) | Tumor Microenvironment and Immune Surevillance | Robert C. Rees - Tumor Immunology and Immunotherapy (2014, Oxford University Press) |
| 6) | Innate Immune Response Against Cancer and Interaction with Innate Immune Cells | Robert C. Rees - Tumor Immunology and Immunotherapy (2014, Oxford University Press) Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola - Cancer Immunotherapy Principles and Practice_ Reflects Major Advances in Field of Immuno-Oncology and Cancer |
| 7) | Adaptive Immune Response Against Cancer and Interaction with Adaptive Immune Cells : CD8 + T cells | Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola - Cancer Immunotherapy Principles and Practice_ Reflects Major Advances in Field of Immuno-Oncology and Cancer Abul K. Abbas MBBS, Andrew H. Lichtman MD PhD, Shiv Pillai MBBS - Cellular and Molecular Immunology (2021, Elsevier) |
| 8) | Adaptive Immune Response Against Cancer and Interaction with Adaptive Immune Cells: CD4+ T cells | Abul K. Abbas MBBS, Andrew H. Lichtman MD PhD, Shiv Pillai MBBS - Cellular and Molecular Immunology (2021, Elsevier) Robert C. Rees - Tumor Immunology and Immunotherapy (2014, Oxford University Press) |
| 9) | Cancer and Microbiota | |
| 10) | Student Presentations-1 | Designated Literature |
| 11) | Student Presentations-2 | Designated Literature |
| 12) | General Evaluation-Summary |
| Course Notes / Textbooks: | 1-Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola - Cancer Immunotherapy Principles and Practice_ Reflects Major Advances in Field of Immuno-Oncology and Cancer 2-Robert C. Rees - Tumor Immunology and Immunotherapy (2014, Oxford University Press) 3-Springer, Attilio Bondanza, Monica Casucci - Tumor Immunology_ Methods and Protocols (2016, Humana Press) 4- Abul K. Abbas MBBS, Andrew H. Lichtman MD PhD, Shiv Pillai MBBS - Cellular and Molecular Immunology (2021, Elsevier) |
| References: |
| Course Learning Outcomes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Program Outcomes | ||||||||||
| 1) To be able to define, evaluate and use current and advanced knowledge of cancer and molecular cancer | ||||||||||
| 2) To be able to research, comprehend and analyze a scientific and technological issue in the field of molecular cancer with a systematic approach. | ||||||||||
| 3) Ability to develop, design, adapt and implement new and complex ideas about the molecular mechanisms of cancer at an expert level with original thinking and/or research | ||||||||||
| 4) To be able to comprehend the interdisciplinary interaction with which the molecular cancer field is related, to develop a new method, design and/or application with a new idea or a known idea. | ||||||||||
| 5) To gain the ability to synthesize, analyze, interpret, question and criticize information about treatment approaches developed against cancer | ||||||||||
| 6) Tp develop new ideas and methods in the field by using high-level skills such as problem solving and decision making in their studies. | ||||||||||
| 7) To have good communication skills in their work and being able to critically examine and develop the norms that guide these relationships, and to manage actions to change them when necessary | ||||||||||
| 8) To have an awareness of ethical responsibility in their research and to be able to defend their findings by using advanced written, verbal and visual communication. | ||||||||||
| 9) To contribute to the solution of social, scientific, computational and ethical problems encountered in the field of molecular cancer and to support the development of these values. | ||||||||||
| 10) To be able to interpret research and study results and expand the limits of knowledge in the field by producing an original work. | ||||||||||
| No Effect | 1 Lowest | 2 Average | 3 Highest |
| Program Outcomes | Level of Contribution | |
| 1) | To be able to define, evaluate and use current and advanced knowledge of cancer and molecular cancer | |
| 2) | To be able to research, comprehend and analyze a scientific and technological issue in the field of molecular cancer with a systematic approach. | |
| 3) | Ability to develop, design, adapt and implement new and complex ideas about the molecular mechanisms of cancer at an expert level with original thinking and/or research | |
| 4) | To be able to comprehend the interdisciplinary interaction with which the molecular cancer field is related, to develop a new method, design and/or application with a new idea or a known idea. | |
| 5) | To gain the ability to synthesize, analyze, interpret, question and criticize information about treatment approaches developed against cancer | |
| 6) | Tp develop new ideas and methods in the field by using high-level skills such as problem solving and decision making in their studies. | |
| 7) | To have good communication skills in their work and being able to critically examine and develop the norms that guide these relationships, and to manage actions to change them when necessary | |
| 8) | To have an awareness of ethical responsibility in their research and to be able to defend their findings by using advanced written, verbal and visual communication. | |
| 9) | To contribute to the solution of social, scientific, computational and ethical problems encountered in the field of molecular cancer and to support the development of these values. | |
| 10) | To be able to interpret research and study results and expand the limits of knowledge in the field by producing an original work. |
| Semester Requirements | Number of Activities | Level of Contribution |
| Midterms | 1 | % 40 |
| Final | 1 | % 60 |
| total | % 100 | |
| PERCENTAGE OF SEMESTER WORK | % 40 | |
| PERCENTAGE OF FINAL WORK | % 60 | |
| total | % 100 | |
| Activities | Number of Activities | Preparation for the Activity | Spent for the Activity Itself | Completing the Activity Requirements | Workload | ||
| Course Hours | 14 | 2 | 1 | 42 | |||
| Study Hours Out of Class | 35 | 0 | 2 | 70 | |||
| Presentations / Seminar | 1 | 25 | 25 | ||||
| Homework Assignments | 1 | 15 | 15 | ||||
| Midterms | 1 | 20 | 1 | 21 | |||
| Final | 1 | 20 | 20 | ||||
| Total Workload | 193 | ||||||